Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Topical composition for treating pain

a topical composition and pain technology, applied in the field oftopical treatment of acute and chronic pain, can solve the problems of increased appetite, increased appetite, increased concentration and awareness, etc., and achieve the effect of reducing or eliminating pain

Inactive Publication Date: 2008-12-18
COMGENRX
View PDF30 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]The composition is applied topically to a site at or adjacent to a painful region. The composition is reapplied as necessary. Pain relief is typically obtained within minutes and lasts for periods of variable duration ranging from minutes to several hours and even, in some cases, days. The compounds are applied such that the dosage is sufficient to provide an effective dose in the painful area or immediately adjacent areas, to ameliorate or eliminate pain. The composition is variably effective to treat visceral, somatic, inflammatory and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness. Examples demonstrate pain relief in human patients for a wide number of conditions, including joint, muscle and tendon pain, joint, muscle and tendon immobility, inflammatory pain, neuropathies, muscle spasms, osteoarthritis, breathing disorders such as wheezing, hunger pains, some types of headaches, dysphagia, fibromyalgia, autoimmune disorders, dysmennorhea, post-surgical pain, anal fissures and visceral pain resulting from chronic and pancreatitis.

Problems solved by technology

In addition, the psychologic component of chronic pain can lead to fatigue, weight gain, increased appetite, decreased concentration and awareness, decreased energy, and psychomotor retardation which often require further adjunctive therapy such as antidepressants and stimulants.
Associated comorbid conditions such as COPD, asthma, and hypertension can lead to dyspnea and decreased exercise tolerance, thereby exacerbating the downward spiral and depression which often characterizes chronic pain syndromes and necessitates further adjunctive treatment.
Moreover, most topical treatments to control pain are of limited efficacy or last only for a few minutes, such as the lidocaine sprays and patches and benzocaine ointments.
Pain of all types can be debilitating both psychologically and physically and exacts an enormous toll in dollars, decreased productivity, and quality of life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Administration of LV with / without an Active Agent to Normal Control Human Patient

[0110]Methods and Materials

[0111]a) Pluronic 20% with 750 mg lactose (Weise compounding pharmacy)

[0112]b) Vanpen (Weise compounding company)

[0113]c) PLO gel (Weise compounding company)—combination of soy lecithin (PCCA) dissolved in 20% pluronic gel made from 405 powder in a ratio of 25% lecithin to 75% pluronic gel

[0114]d) Lecithin soya dissolved in isopropyl myristate (Weise compounding company)

[0115]e) PLO (Advanced Rx compounding pharmacy)—combination of lactose (750 mg) with propylene glycol to we, 9 mL soy lecithin isopropyl palmitate and 20% pluronic gel (30 mg)

[0116]Atenolol (Advanced Rx compounding pharmacy)

[0117]Clonidine (Advanced Rx compounding pharmacy)

[0118]Nitrobid

[0119]Surgilube (applied as control)

[0120]Formulations were applied to skin with a tongue depressor.

[0121]Treatment and Observation

[0122]Application of (a) on skin resulted in numbness similar to that produced by lidocaine.

[0123...

example 2

Administration of LV with / without an Active Agent to Human Patient with Neck Pain

[0127]Materials and Methods

[0128]Formulations were as in Example 1.

[0129]Patient presented with stiff neck with an inability to rotate it past 70 degrees to the right and a rotator cuff tendinopathy. Pain Level −4 / 10. Stiffness with an inability to move her shoulder past 70 degrees.

[0130]Treatment and Observation

[0131]Adding (e) resulted in a very slight effect on the shoulder.

[0132]Adding (c) reduced the pain to 3 / 10 and made shoulder more mobile. Adding (d) seemed to have no effect.

[0133]Adding (e) plus Atenolol 25 mg dissolved in lactose, propylene glycol, soy lecithin / isopropyl palmitate, 20% pluronic gel had a strong effect reducing pain to 0.5 / 10 and made her shoulder much more mobile.

[0134]Adding to (e) clonidine 0.8 mg dissolved in lactose, propylene glycol, soy lecithin / isopropyl palmitate, 20% pluronic gel mixed with 2% nitrobid made the pain disappear completely and restored full mobility. In...

example 3

Administration of LV with / without an Active Agent to Human Patient with Shoulder and Neck Pain from Tendonopathy

[0135]Materials and Methods

[0136]Formulations were the same as in Example 1.

[0137]The patient presented with Pain level=9 / 10 on shoulder / neck pain from a rotator cuff tendonopathy and inability to move his shoulder past the horizontal. Pain Level=7 / 10 left knee pain due to patellofemoral syndrome; Pain level=9 / 10 from a left sacroiliac strain.

[0138]Treatments and Observation

[0139]Shoulder: Applying 25 mg Atenolol dissolved in (e) decreased pain to 5 / 10 and patient noted that his skin felt warm and mobility was improved.

[0140]The clonidine+nitrobid combination was added with no change.

[0141]Then VanPen gel was added and pain disappeared with full mobility remaining.

[0142]Knee: Adding (e) decreased pain to 2 / 10 with no change in mobility. Clonidine 0.6 mg+nitrobid (2% nitrate) were applied with no change in pain or mobility.

[0143]Back (sacroiliac strain): Applied (e) and pai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Compositionaaaaaaaaaa
Acidityaaaaaaaaaa
Hydrophilicityaaaaaaaaaa
Login to View More

Abstract

Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. In the preferred embodiment, the formulation is a gel. The LV may contain a penetration enhancer, most preferably one with membrane disruptive properties. The formulation may be applied to or impregnated into a gauze, wrap, bandage, cotton-tipped stick, adhesive bandage strip, or other support wrap or medical bandage or wound cover. For example, the compositions may be are incorporated onto or into disposables such as hemorrhoid wipes, sponge, mouth guards, dental trays; needles or catheters; adult diapers; gloves, socks or wrist bands, for ease of application. The composition is applied topically to a site at or adjacent to a painful region. The composition is reapplied as necessary. Pain relief is typically obtained within minutes and lasts for periods of variable duration ranging from minutes to several hours and even, in some cases, days. The composition is variably effective to treat visceral, somatic and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 11 / 851,241, filed Sep. 6, 2007, which claims the benefit of U.S. Provisional Application Ser. No. 60 / 943,552, filed Jun. 12, 2007, each of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to a topical treatment of acute and chronic pain, which is somatic, visceral, or neuropathic, as well as joint and muscle stiffness. This treatment also addresses to some degree the psychologic, vegetative and medication-induced sequelae of pain (usually chronic) which can include fatigue, decreased alertness, weight gain, decreased exercise tolerance, and dyspnea.BACKGROUND OF THE INVENTION[0003]Pain is a sensation and a perception that is comprised of a complex series of mechanisms. In its most simple construction, it is a signal from the firing of nociception, touch and pressure receptors in the periphery that is transmitt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/00A61K31/685A61K31/23A61K35/00A61K31/56A61K36/185A61K36/87
CPCA61K9/0014A61K31/01A61K31/045A61K31/56A61K31/215A61K31/23A61K31/19A61P1/14A61P3/04A61P11/00A61P11/08A61P17/00A61P19/02A61P21/00A61P25/00A61P25/04A61P29/00A61P29/02A61K9/0009A61K31/685
Inventor ORONSKY, BRYAN T.ORONSKY, NEIL C.ORONSKY, ARNOLD L.
Owner COMGENRX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products